Bal Pharma Board of Directors
Get the latest insights into the leadership at Bal Pharma. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Shailesh D Siroya | Managing Director |
| Mr. Himesh Virupakshaya | Executive Director |
| Mr. Jatish Sheth | Independent Director |
| Dr. C V Srinivas | Independent Director |
| Ms. Nicloa Neeladri | Independent Director |
| Mr. H S Venkatesh | Independent Director |
| Mr. Kotian Chittananda Damodar | Executive Director |
Bal Pharma Share price
BALPHARMA
86.94
2.46 (-2.75%)NSE
BSE
Last updated on 4 Sep, 2025 | 15:28 IST
BUYSELL
Today's High
91.49
Today's Low
86.00
52 Week Low
78.06
52 Week High
142.70
The current prices are delayed, login to your account for live prices
LoginBal Pharma FAQs
The board at Bal Pharma consists of experienced professionals, including Mr. Shailesh D Siroya , Mr. Himesh Virupakshaya , and others, overseeing the company’s strategic and corporate governance.
Directors at Bal Pharma are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Shailesh D Siroya is the current chairman at Bal Pharma.
Executive directors at Bal Pharma are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Bal Pharma adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Bal Pharma, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.